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Abstract: 
The main aim of the present investigation was to optimize the fermentation parameters that 
enhance the maximum production of lovastatin by Aspergillus fischeri using coconut oil cake as 
the solid substrate under solid state fermentation. The maximum yield of lovastatin (14.77 mg/g 
dry substrate) using coconut oil cake as the substrate was achieved with the following optimized 
process parameters: fermentation time (7 days), initial moisture content (60% v/w), inoculum 
volume (2ml of five day old culture), initial pH (5.0), incubation temperature (30ºC), lactose (1% 
w/v) and malt extract (1% w/v).  
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Introduction:  
Lovastatin also called as Mevinolin, 
Monacolin K and Mevacor, a kind of fungal 
metabolite, serves as one of the competitive 
inhibitors of enzyme hydroxymethylglutaryl 
coenzyme A reductase (HMG-CoA), which 
catalyzes the rate-limiting step in cholesterol 
biosynthesis, resulting in lowered blood 
cholesterol [1,2]. In addition, lovastatin has 
been used in the biomedical applications such  
 
as, in treating coronary heart diseases, renal 
diseases, Alzheimer’s disease, bone fractions 
[3]. Moreover, it has been indicated as a 
potential therapeutic agent for the treatment of 
various types of tumors because of its 
capability to suppress tumor growth in vivo 
through inhibition of the synthesis of non-
sterol isoprenoid compounds [4, 5]. 
Commercial production of lovastatin has been 
carried out by submerged fermentation using 
different microorganisms [6, 7]. In recent 
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years, researchers have shown an increasing 
interest in solid state fermentation (SSF) as it 
is a potential alternative of submerged 
fermentation because economical and cheap 
substrates can be utilized in SSF for 
production of value-added products, and also 
requires less energy, and low capital costs. 
Now days, SSF has been exploited for the 
production of highly potent drugs on large 
scale. But still, few reports are available on 
the microbial production of lovastatin under 
SSF [8-10]. 
In the present study, we evaluated the 
feasibility of SSF process for lovastatin 
production by Aspergillus fischeri and 
optimized different process parameters that 
maximize the lovastatin yield. 
Materials and Methods 
Microorganism and Inoculum preparation: 
The fungal strain Aspergillus fischeri NCIM 
509 used in this study was procured from the 
culture collection centre of National 
Collection of Industrial Microorganisms 
(NCIM), NCL, Pune.  The microbial strain 
was maintained on Potato Dextrose Agar 
(PDA) slants containing (g/l) dextrose 20.0 
and agar 15.0. Inoculated slants were grown in 
an incubator at 28°C for 5 days. After that, the 
slants were preserved at 4°C and sub-cultured 
once every four weeks (monthly). 
Inoculum preparation: 
Inoculum was prepared by adding 10 ml of 
sterilized 0.1% Tween 80 solution to a well-
sporulated A. fischeri slant. The spore surface 
was scrapped with an inoculating loop to 
suspend the spores in the solution and the 
obtained spore suspension was used as the 
inoculum for the fermentation process. 
Solid state fermentation (SSF): 
Coconut oil cake obtained from the local 
market of Vijayawada, Andhra Pradesh was 
used as the substrate in the present study. Five 
grams of coconut oil cake was dried and 
grounded to required particle size having both 
coarse and fine particles in 1:1 ratio (w/w). 
The  substrate was taken in a 250ml 
Erlenmeyer flask and moistened with distilled 
water to maintain the moisture content of 50% 
(v/w) and autoclaved at 121ºC (15lb) for 15-
20 min, cooled to room temperature and 
inoculated with 2 ml of the 5 day spore 
suspension (spore concentration of about 107-108 
per ml) of A. fischeri under aseptic conditions. 
The contents of the inoculated flasks were 
mixed thoroughly and incubated at desired 
temperature in an incubator for desired length 
of fermentation time. 
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Optimization of Process Parameters: 
Various process parameters that influence the 
lovastatin production during SSF were 
optimized over a wide range. The strategy 
adopted for standardization of fermentation 
parameters was to evaluate the effect of an 
individual parameter and incorporate it at the 
standard level before standardizing the next 
parameter. The process parameters optimized 
in the present study include fermentation time 
(24-192h), initial moisture content (40-100% 
v/w), inoculum volume (0.5-4ml), initial pH 
(4-10), incubation temperature (26-40˚C), 
carbon sources (1% w/v) and nitrogen sources 
(1% w/v). All the experiments were done in 
triplicate and the mean values of the lovastatin 
yield was reported. 
Lovastatin extraction: 
After the fermentation time, the fermented 
flasks were dried at 60°C for 2 hrs. To this 20 ml 
of methanol was added to the flasks to extract 
lovastatin by keeping them in an orbital shaker at 
180 rpm for 2 h. The residue was filtered with 
filter paper and then centrifuged at 1500 rpm for 
15 min. The supernatant obtained was 
collected and analyzed for quantitative 
determination of lovastatin [10]. 
Quantitative analysis of lovastatin: 
To 1 ml of the obtained supernatant, 1 ml of 
1% Trifloroacetic acid was added and 
incubated for 10 min (Lactonization of 
hydroxyl acid form of Lovastatin).From the  
solution, 0.5 ml was taken and diluted to 10-
100 ml in methanol and its absorbance was 
read at 238 nm by using UV-Visible 
Spectrophotometer [11]. 
 
 
Concentration of Lovastatin (mg/g)   =  Concentration of Lovastatin (mg/ml) x Dilution factor (DF) 
                                                                       Amount of substrate taken (g) 
 
Results and Discussion 
Selection of solid substrates in SSF for 
lovastatin production: 
Solid substrates employed in SSF processes 
are heterogeneous natural raw-materials which 
are generally insoluble in water and play a  
 
 
dual role-supply of nutrients to the microbial 
culture growing and anchorage for the 
growing cells. In the present study, coconut oil 
cake was used as the solid substrate for both 
the fungal sporulation and lovastatin 
production by Aspergillus fischeri. Maximum 
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lovastatin yield of 6.81 mg/g dry substrate was 
obtained.  
Effect of Fermentation time: 
The effect of fermentation time on lovastatin 
production was studied by incubating the 
fermentation flasks from 24-192 h. The 
maximum lovastatin yield of 7.43 mg/g of dry 
substrate was achieved at 168 h of 
fermentation time (Fig.1). The lovastatin yield 
increased from    24-168 h which explained 
that lovastatin is a kind of secondary 
metabolite and its accumulation in mycelia 
seems growth related and slightly decreased 
from 168-192h. The lovastatin yield decreased 
after seven days (168 h) of fermentation which 
may be due to the onset of death phase of 
microorganism and nutrient depletion.  
Fig.1: Effect of fermentation time on lovastatin production 
Effect of initial moisture content 
To investigate the influence of initial 
moisture content of the substrate, 
fermentation was carried out under various 
initial moisture content levels (40, 50, 60, 
70, 80, 90 and 100(% v/w)) of coconut oil 
cake, which was adjusted with moistening 
media. Maximum lovastatin yield (8.04 
mg/g dry substrate) was achieved at 60% 
(v/w) initial moisture content ( Fig. 2.).   
As the moisture content in the fermentation 
medium increases, the air present in the void 
volume decreases, resulting in poor oxygen 
availability for the process without forced 
aeration and with low moisture content, the 
available oxygen is sufficient but the water 
content is not enough to support good 
metabolic activity and dissipation of heat 
generated and may account for lower 
lovastatin production. The same 60% (v/w) 
moisture content was also observed for both 
Aspergillus flavipes and Aspergillus terreus 
under SSF [8, 10].  
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Fig. 2: Effect of moisture content on lovastatin production 
Effect of Inoculum volume 
Fermentation was carried out with different 
inoculum volumes (0.5-4ml) of five day old 
A. fischeri culture for a period of 144h to 
study its effect on lovastatin production. The 
maximum yield of lovastation (8.97 mg/g 
dry substrate) was obtained with 2ml of 
A.fischeri culture as shown in Fig. 3. 
 
 
With the further increase in inoculum 
volume, the yield of lovastatin had 
decreased which might be due to the 
depletion of the available nutrients in the 
production medium, yielding poor mycelia 
growth, thus promoting less product 
formation. With low inoculum volume, the 
yield is also low due to the insufficient 
microbial culture to form mycelia and 
produce lovastatin. 
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Fig. 3: Effect of inoculum volume on lovastatin production 
 
Effect of initial pH: 
Experiments were performed to the 
optimum pH in order to maintain the 
favorable conditions for increased 
production of lovastatin. This was 
established by carrying out the fermentation 
by varying the pH from 4-10. 
The profound effect of initial pH of the 
fermentation on lovastatin production was as 
shown in Fig. 4. Maximum lovastatin yield  
 
 
(9.71 mg/g dry substrate) was recorded at 
pH 5.0. A further increase in pH resulted in 
gradual decrease of lovastatin production 
due to the denaturation or inactivation of the 
microbial strain, because pH strongly 
influences the transport of various components 
across the cell membrane which support the cell 
growth and product formation, and most of the 
fungi are active in the pH range of 3.5-7 and also 
lower pH avoids the contamination by other 
microbes. The result was in accordance with 
the lovastation production using Aspergillus 
terreus under SSF [8]. 
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Fig. 4: Effect of pH on lovastatin production. 
 
Effect of temperature 
Fermentation was carried out at various 
temperatures from 26-40°C to study their 
effect on enzyme production (Fig. 5). 
Results indicated that maximum lovastatin 
production (10.88 mg/g dry substrate) was 
obtained when SSF was carried out at 30°C. 
However, lovastatin production reduced 
gradually above the optimal incubation 
temperature of 30°C. With further increase  
 
in temperature, more heat is accumulated in 
the medium during mesophilic aerobic SSF, 
which leads to poor heat dissipation thus 
reducing the oxygen level and thereby 
reducing the growth of microorganism, as 
lovastatin is growth related product. These 
results are coinciding with those previously 
reported for lovastatin production by 
Aspergillus terreus and Monascus ruber 
[10,13]. 
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Fig. 5: Effect of temperature on lovastatin production 
 
Effect of carbon source  
To determine the effect of incorporation of 
additional carbon sources on lovastatin 
yield, different carbon sources namely 
glucose, maltose, sucrose, xylose, lactose, 
galactose and soluble starch at 1% (w/v) 
added to the basal solid state fermentative 
medium of A. fischeri exerted a considerable 
effect on the biosynthesis of lovastatin (Fig. 
6). Maximum lovastatin production was 
promoted by lactose (12.02 mg/g dry 
substrate) followed by maltose (11.11 mg/g 
dry substrate) and sucrose (10.47 mg/g dry 
substrate). The enhanced production of 
lovastatin by the incorporation of lactose to 
the medium might be attributed to the 
positive influence of lactose as a co-
metabolic agent for enhanced microbial 
metabolite biosynthesis.  
 
Fig. 6: Effect of different carbon sources on lovastatin 
production. 
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Effect of Nitrogen source 
Nitrogen source can be an important limiting 
factor in the production of microbial 
metabolites [14]. The supplementation of 
additional nitrogen sources (either organic or 
inorganic) such as sodium nitrate, ammonium 
sulphate, urea, peptone, tryptone, yeast 
extract, malt extract and beef extract at 1% 
(w/v) had shown a profound impact on the 
production of lovastatin by A. fischeri under 
SSF ( Fig. 7). 
Among the various nitrogen sources 
evaluated, malt extract in the fermentation 
medium promoted enhanced fungal growth 
and consequent lovastatin production of 14.77 
mg/g dry substrate was achieved followed by 
yeast extract (12.36 mg/g dry substrate) and 
sodium nitrate (11.03 mg/g dry substrate).  
 
Fig. 7: Effect of different nitrogen sources on lovastatin 
production 
 
Conclusion: 
The current investigation was mainly 
focused on the evaluation of the potentiality 
of Aspergillus fischeri for utilization of 
coconut oil cake as the substrate for the 
production of lovastatin under solid state 
fermentation. The yields obtained in the 
present study have to be further increased 
for its industrial importance. It has proved 
the feasibility of solid state fermentation as a 
promising technique in exploiting cheaply 
available agro-residual wastes as substrates 
for the large-scale production of microbial 
metabolites of biotechnological importance 
ultimately leading to an effective solid waste 
management. 
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